Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Overview

cited authors

Mann, Johannes F. E.; Buse, John B.; Idorn, Thomas; Leiter, Lawrence A.; Pratley, Richard E.; Rasmussen, Soren; Vilsboll, Tina; Wolthers, Benjamin; Perkovic, Vlado

authors

Pratley, Richard Edwin, MD

Publication Date

June 1, 2021

webpage

Web of Science

published in

DIABETES OBESITY & METABOLISM Journal

Research

keywords

chronic kidney disease
glucagon-like peptide-1 receptor agonist
kidney mediation
liraglutide
semaglutide
type 2 diabetes

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.